Matthias Will, MD

Matthias Will, MD

Chief Development Officer (CDO) @ Autolus Therapeutics

About

I am passionate to bringing effective therapies to cancer patients. As a physician trained in oncology as well as skilled in commercialization strategy, I am uniquely qualified to change the paradigm of cancer care and enable physicians and payors to provide the best medical care possible. In the past 10 years, my teams have launched 5 new products, guided the expansion of the oncology portfolio and partnered with several of the Top 20 pharma companies. I thrive in tackling complex challenges within a fast moving environment where I can build and nurture successful and accountable teams.

Country

United States

City

San Francisco Bay Area

Industry

Biotechnology

Skill

Regulatory Submissions, Clinical Strategy, Translational Medicine, Approval Process, Oncology, Pharmaceutical Industry, Medical Devices, Clinical Research, Product Launch, Healthcare, Cardiology, Clinical Development, Global Marketing, Clinical Trials, Health Economics, Diabetes, German, French, Market Access, Pharmaceutical Sales

Experience

Autolus Therapeutics

Chief Development Officer (CDO)

Autolus Therapeutics

LinkedIn
2024-9 - Present · 2 yrs 1 mo

San Francisco Bay Area

Leading a world class team of development experts to bring new cell therapies to patients suffering from life threatening diseases.

Dren Bio

Chief Medical Officer

Dren Bio

LinkedIn
2021-10 - 2024-9 · 3 yrs

San Francisco Bay Area

Building and leading the development organization to develop the first-in-class CD94 antibody in T-cell lymphomas and auto-immune diseases and the myeloid cell engaging bispecifics for vairous tumor types.

CRISPR Therapeutics

VP Clinical Development

CRISPR Therapeutics

LinkedIn
2019-7 - 2021-10 · 2 yrs 4 mos

San Francisco Bay Area

Led the clinical development of the first in class allogeneic CRISPR gene edited CAR T cell program targeting CD70 in T cell lymphomas and RCC as well as the partnered gene engineered NK cell program.

CytomX Therapeutics

VP Clinical Development

CytomX Therapeutics

LinkedIn
2017-10 - 2019-7 · 1 yr 10 mos

South San Francisco, California

Led a team of MDs and clinical scientist to file 4 INDS and develop drugs to mid-stage clinical development, stand-alone as well as pharma partnered programs

CytomX Therapeutics

Senior Director Clinical Development

CytomX Therapeutics

LinkedIn
2016-8 - 2017-10 · 1 yr 3 mos

South San Francisco

Preparing our first-in-human study for CytomX proprietary Probody platform, proteins such as antibodies cleaved by proteases only active in the tumor microenvironment.

Gilead Sciences

Medical Director Oncology

Gilead Sciences

LinkedIn
2014-3 - 2016-8 · 2 yrs 6 mos

Foster City, CA

Supported the approval of the first Pi3K inhibitor and development of additional indications.

Novartis

Head Medical Affairs and Marketing MDx

Novartis

LinkedIn
2011-7 - 2014-1 · 2 yrs 7 mos

San Diego, CA

Late-stage development and product launch of several targeted therapies (Pi3K, PTEN, FGF, FLT-3) with their respective companion diagnostics in Oncology

Novartis

Head Marketing & Market Access Companion Diagnostics

Novartis

LinkedIn
2007-9 - 2011-7 · 3 yrs 11 mos

Developed and implemented strategies for access to targeted therapies (TKIs) in conjunction with companion diagnostics for Oncology products

Novartis

Director

Novartis

LinkedIn
2007-9 - 2009-1 · 1 yr 5 mos

Basel Area, Switzerland

Led strategic project for the Novartis Group and Novartis Pharma

GE HealthCare

Business manager

GE HealthCare

LinkedIn
2005 - 2007 · 2 yrs

•Orchestrated project delivery to strategic clients in Central Europe and the Middle East in support of large public-private partnership engagements investment and service agreements. •Proved integral to a variety of projects including capital and performance agreements with cancer care hospital systems located in Europe and the Middle East

McKinsey & Company

Engagement Manager

McKinsey & Company

LinkedIn
2001 - 2005 · 4 yrs

Offices: COL, LON, NEJ Selected studies include: •Defined a new Market Access Strategy to counter austerity measures such as “jumbo group pricing” for a Top 10 global pharma player in EU5 markets. •Integrated a new anti-coagulation franchise for global pharma players. •Aligned sales forces in Poland, Hungary, and Czech Republic for a top generic player as a component of post-merger integration

University of Tübingen

Residency in Hematology & Oncology

University of Tübingen

2000 - 2001 · 1 yr

Tübingen Area, Germany

Education

Harvard Medical School

Harvard Medical School

LinkedIn

Medicine

1999 - 1999
Medizinische Hochschule Hannover

Medizinische Hochschule Hannover

LinkedIn

Medicine

1997 - 1999 · 2 yrs
Université de Rennes I

Université de Rennes I

LinkedIn

Medicine

1995 - 1996 · 1 yr
The University of Bonn

The University of Bonn

LinkedIn

Medicine

1992 - 1995 · 3 yrs

Matthias Will, MD's Contact Information

Email

******@***.com

Phone

(**) *** ****

Find the Right Leads
Find Verified Contact Data

Try with: Jensen Huang @ nvidia.com Click to autofill
LeadContact awards, five-star ratings, and GDPR compliance badges

What LeadContact does well

Find verified emails, phone numbers, and decision-makers with 98% accuracy.

Find Leads

Find Leads

Find the right people by company, role, industry, location, and more.

925M+ professional profiles

Find Leads
Find Emails

Find Emails

Access verified email addresses for your target contacts.

657M+ emails

Find Emails
Find Phone Numbers

Find Phone Numbers

Get cross-validated phone data from multiple top sources.

239M+ phone numbers

Find Phone Numbers

More Accurate. Lower Cost.

Find contact data in 1 tool with 98% accuracy

LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.

LeadContact Logo
Competitor Tools

All these = $289 per month

Great conversations start with the right contact.

It’s time to find yours.